Paul Hastings Advises Ligand Pharmaceuticals on Its $400 Million Convertible Notes Offering

Paul Hastings LLP advised Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines, in connection with its private placement of $400 million aggregate principal amount of 0.75% convertible senior notes due 2030. The offering is expected to close on August 14, 2025, subject to customary closing conditions.

Securities & Capital Markets partner Brandon Bortner and of counsel Ryan Brewer led the Paul Hastings team, which also included partners Daniel Nicholas and Jaime Madell and associates Greg Drozdzal and Gaby Jassir. Public Company Advisory partners Brad Bondi and Sean Donahue assisted on governance matters.

More details can be found here.

About Paul Hastings

With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.